The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Drug Rediscovery Protocol (DRUP Trial) (DRUP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02925234
Recruitment Status : Recruiting
First Posted : October 5, 2016
Last Update Posted : January 24, 2024
Sponsor:
Collaborators:
Amgen
AstraZeneca
Bayer
Bristol-Myers Squibb
Novartis
Roche Pharma AG
Merck Sharp & Dohme LLC
Boehringer Ingelheim
Ipsen
Eisai Inc.
Pfizer
Clovis Oncology - Pharma and
Eli Lilly and Company
Janssen, LP
GlaxoSmithKline
Incyte Corporation
Dutch Cancer Society
Stelvio for Life
Information provided by (Responsible Party):
The Netherlands Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 2027
Estimated Study Completion Date : December 2027
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):